BLLN BillionToOne, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2070849 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY71.9%
TTM net income YoY593.9%
TTM EPS YoY183.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin71.4%
Operating margin10.2%
Net margin11.3%
FCF margin7.8%
EBITDA margin11.9%
Returns
ROE30.2%
ROA9.1%
ROIC (approx.)—
Asset turnover0.80x
Leverage & solvency
Liabilities / assets25.5%
Debt / equity0.16x
Current ratio11.25x
Interest coverage1,655.26x
Cash quality & payout
Operating cash flow / net income0.97x
Accruals ratio0.3%
Payout ratio—
Capex / revenue3.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | $305.11M | $152.58M | $71.73M |
| Cost of revenue | $96.65M | $71.67M | $54.42M |
| Gross profit | $208.46M | $80.92M | $17.31M |
| R&D expense | $49.38M | $36.60M | $22.41M |
| SG&A expense | $143.05M | $91.47M | $64.39M |
| Operating income | $16.02M | -$47.15M | -$69.50M |
| Interest expense | $95,000 | $2.39M | $3.27M |
| Pretax income | $7.76M | -$41.54M | -$82.67M |
| Income tax | $305,000 | $29,000 | $9,000 |
| Net income | $7.45M | -$41.57M | -$82.68M |
| EBITDA | $22.92M | -$40.15M | -$63.59M |
| EPS (basic) | 0.18 | -4.12 | -8.45 |
| EPS (diluted) | 0.14 | -4.12 | -8.45 |
| Weighted avg. shares (diluted) | 21.23M | 10.08M | 9.78M |
| Balance sheet | |||
| Cash & equivalents | $495.98M | $191.48M | $97.27M |
| Receivables | $41.62M | $24.71M | — |
| Inventory | $17.55M | $8.73M | — |
| Current assets | $560.56M | $227.82M | — |
| PP&E, net | $20.36M | $17.11M | — |
| Total assets | $632.65M | $302.06M | — |
| Current liabilities | $47.96M | $28.39M | — |
| Short-term debt | $0 | $0 | — |
| Long-term debt | $57.23M | $51.48M | — |
| Total debt | $57.23M | $51.48M | — |
| Total liabilities | $152.55M | $134.31M | — |
| Shareholders' equity | $480.11M | -$251.66M | -$219.05M |
| Net debt | -$438.75M | -$140.00M | — |
| Shares outstanding | — | 10.93M | — |
| Cash flow statement | |||
| Operating cash flow | $24.59M | -$41.38M | -$53.67M |
| Capital expenditure | $8.88M | $5.40M | $6.17M |
| Free cash flow | $15.71M | -$46.78M | -$59.85M |
| Investing cash flow | -$8.92M | -$5.43M | $82.84M |
| Financing cash flow | $288.82M | $141.02M | $13.40M |
| Depreciation & amortization | $6.90M | $7.00M | $5.90M |
| Stock-based compensation | $15.91M | $8.36M | $4.85M |
| Share buybacks | $0 | $546,000 | $0 |
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.